vimarsana.com

Latest Breaking News On - Discrete choice - Page 1 : vimarsana.com

DaVita Clinical Research Showcases Chronic Kidney Disease and Rare Disease Network, Presents New Research Findings at Kidney Week 2022

/PRNewswire/ DaVita Clinical Research (DCR) will highlight its latest research during the American Society of Nephrology (ASN) Kidney Week, being held in.

United statesSteven brunelliKaren modlinDavita incRelationship between driving time to transplant centerDavita clinical researchChronic kidney disease rare networkPrnewswire davita clinical researchRare disease networkAmerican society of nephrologyChronic kidney diseaseVita clinical researchAmerican societyKidney weekEnd of life care among dialysis patientsDiscrete choice

Retrofitting Buildings to Reduce Carbon

A modular carbon-neutral housing retrofit startup, ecoworks, has recently raised $7.7 million in private funding to deliver its carbon-free retrofitting project for existing residential buildings.

Ben pilkingtonAlessandro cancian shutterstockBen pilkingtonjulCameris shutterstockEnergy efficiency directiveWarema groupEuropean unionEnergy performance of buildings directiveEnergy performanceBuildings directiveRetrofitting ratesGlobal ventureZacua venturesBlackhorn venturesUnited states basedMotu ventures

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022

/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and.

United statesEiryw robertsNeurocrine biosciencesAcademy of managed care pharmacyDrug administrationPrnewswire neurocrine biosciences incManaged care pharmacyChief medical officerUnmet needsClassic congenital adrenal hyperplasiaModified delphi consensusResource utilizationClassic congenital adrenalMedication preferencesDiscrete choice

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing.

United statesPaul limburgCara connellyKevin conroyMegan jonesSciences corpSciences on facebookSciences on twitter exactsciencesExchange commissionPrnewswire exact sciences corpPanel reliably detects colorectal cancerGenomic health incSciences corporationUs preventive services taskScreening at exact sciencesNational comprehensive cancer network

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing.

United statesPaul limburgCara connellyKevin conroyMegan jonesSciences corpSciences on facebookSciences on twitter exactsciencesExchange commissionPrnewswire exact sciences corpPanel reliably detects colorectal cancerGenomic health incSciences corporationUs preventive services taskScreening at exact sciencesNational comprehensive cancer network

vimarsana © 2020. All Rights Reserved.